Brentuximab vedotin (Adcetris)

This slideshow reviews brentuximab vedotin (Adcetris), indicated for treatment of Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) and systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multiagent chemotherapy regimen.